Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.76 USD

88.76
5,165,991

-0.24 (-0.27%)

Updated Oct 28, 2024 04:00 PM ET

After-Market: $88.76 0.00 (0.00%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

by Zacks Equity Research

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine

by Zacks Equity Research

Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

New Strong Sell Stocks for February 10th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

Neena Mishra headshot

Can Biotech ETFs Continue to Soar in 2020?

by Neena Mishra

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

Company News for Feb 6, 2020

by Zacks Equity Research

Companies In The News Are: COTY, CPRI, HUM, GILD.

Sheraz Mian headshot

Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates

by Sheraz Mian

In addition to featuring fresh research reports on Exxon (XOM), Chevron (CVX), IBM (IBM) and others, today's Research Daily provides the Q4 earnings season update.

Regeneron Expands Agreement to Develop Coronavirus Therapy

by Zacks Equity Research

Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

by Zacks Equity Research

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap

Mark Vickery headshot

Disney, Gilead & Snap Post Mixed Quarters, Chipotle Beats

by Mark Vickery

Lots of fresh Q4 earnings results to sift through after Tuesday's closing bell, so we will dive right in.

Gilead Sciences (GILD) Misses Q4 Earnings Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -22.62% and 2.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Company News for Feb 4, 2020

by Zacks Equity Research

Companies in the news are: GILD, MAXR, INSM, ABG

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Should You Buy Gilead (GILD) Ahead of Earnings?

by Zacks Equity Research

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.

Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.

J&J (JNJ) Plans to Develop Vaccine for New Coronavirus

by Zacks Equity Research

J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.